TABLE 3.
Distribution of amino acids at HIV RT positions associated with drug resistance in 46 plasma samples
| Positiona | Amino acid in HXB2 | Mutation(s)b | Amino acid(s)c in:
|
Discordancesd (n) | |
|---|---|---|---|---|---|
| A1 | B1 | ||||
| 41 (N) | M | M41L | M (32), LM (1), L (13) | M (32), LM (1), L (13) | |
| 44 | E | E44D | E (43), DE (1), D (2) | E (44), D (2) | 1 |
| 62 | A | A62V | A (45), V (1) | A (45), V (1) | |
| 65 (N) | K | K65R | K (45), R (1) | K (45), R (1) | |
| 67 (N) | D | D67N | D (33), N (9), G (4) | D (34), N (8), G (4) | 1 (C) |
| 69 (N) | T | T69D/N/S/A | T (42), S (1), D (2), AT (1) | T (43), S (1), D (2) | 1 |
| 70 (N) | K | K70R | K (39), R (7) | K (40), R (6) | 1 (C) |
| 74 (N) | L | L74I/V | L (41), I (2), V (3) | L (40), I (2), LV (1), V (3) | 1 |
| 75 (N) | V | V75T/I/M/A | V (44), AITV (1), T (1) | V (44), T (1), AT (1) | |
| 77 | F | F77L | — | — | |
| 100 | L | L100I | L (45), I (1) | L (45), I (1) | |
| 101 | K | K101E | K (42), E (2), KR (2) | K (42), R (1), E (2) KR (1) | 1 |
| 103 (NN) | K | K103N | K (37), KN (1), N (8) | K (37), KN (1), N (8) | |
| 106 (NN) | V | V106A | V (41), A (1), I (3), IV (1) | V (41), I (3), AV (1), IV (1) | 1 |
| 108 | V | V108I | — | — | |
| 115 | Y | Y115F | — | — | |
| 116 | F | F116Y | — | — | |
| 118 | V | V118I | V (39), I (7) | V (40), I (6) | 1 (C) |
| 151 (N) | Q | Q151M/L | — | — | |
| 181 (NN) | Y | Y181C/I | Y (42), C (4) | Y (42), C (4) | |
| 184 (N) | M | M184V/I | M (28), MV (1), V (17) | M (29), V (17) | 1 |
| 188 (NN) | Y | Y188C/L/H | Y (45), L (1) | Y (45), L (1) | |
| 190 (NN) | G | G190A/S | G (41), A (3), S (1), E (1) | G (41), A (3), S (1), E (1) | |
| 210 (N) | L | L210W | L (34), LW (1), P (1), W (10) | L (34), LW (1), F (1), W (10) | |
| 215 (N) | T | T215Y/F | T (25), FS (1), Y (12), C (1), N (4), F (2), ST (1) | T (26), FS (1), Y (11), C (1), N (4), P (3) | 2 (1C) |
| 219 (N) | K | K219Q/E/N | K (34), Q (5), E (2), N (5) | K (33), Q (5), KQ (1), E (2), N (5) | |
| 225 | P | P225H | — | — | |
| 236 (NN) | P | P236L | — | — | |
a
N, key or secondary nucleoside analogue-associated RT inhibitor mutation; NN, key nonnucleoside RT inhibitor mutation.
b
T69D/N/S/A stands for T69D, T69N, T69S, or T69A.
c
—, complete match with HXB2. Numbers in parentheses represent the numbers of samples for the observed amino acid or mixture.
d
C, complete discordance.